The document discusses various perspectives on the optimal timing of protein formulation development. It notes that some experts recommend completing formulation before Phase I trials to address issues that cause drug failures, while others pursue formulation development throughout the drug development process as more data becomes available. The document also explores challenges like material limitations early in development and the rise of complex combination products. High-throughput screening and rational stepwise approaches to formulation are discussed.